Gilead rescues biopharma’s takeout scene

The spiralling cost of assets seems to have put many would-be biopharma buyers off doing big acquisitions. Not so Gilead, whose $21bn purchase of Immunomedics prevented the third quarter from being a complete disaster for deal bankers.

Without the Immunomedics takeout the total spent last quarter looks very pedestrian, at least compared with previous years.